| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2917.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass.
Correspondence to Haim D. Danenberg, MD, MIT Building 56-322, 77 Massachusetts Ave, Cambridge, MA 02139. E-mail danen{at}mit.edu
| Abstract |
|---|
|
|
|---|
Methods and Results Rabbits subjected to iliac artery balloon injury (balloon denudation with or without stent deployment) were injected twice with a bacterial lipopolysaccharide (LPS) (500 ng/rabbit) before and after surgery. The dose was chosen to be sufficient to induce systemic inflammation but not septic shock. A systemic marker of inflammation (serum interleukin-1ß levels measured by ELISA) and monocytic stimulation (CD14 levels on monocytes measured by flow cytometry) were increased after LPS administration. Arterial macrophage infiltration at 7 days after injury was 1.7±1.2% of total cells in controls and 4.2±1.8% in LPS-treated rabbits (n=4, P<0.05). Morphometric analysis of the injured arteries 4 weeks after injury revealed significantly increased luminal stenosis (38±4.2% versus 23±2.6, mean± SEM; n=8, P<0.05) and neointima-to-media ratio (1.26±0.21 versus 0.66± 0.09, P<0.05) in LPS-treated animals compared with controls. This effect was abolished by anti-CD14 Ab administration. Serum interleukin-1ß levels and monocyte CD14 expression were significantly increased in correlation with the severity of intimal hyperplasia. LPS treatment increased neointimal area after stenting from 0.57±0.07 to 0.77± 0.1 mm2 and stenosis from 9±1% to 13±1.7% (n=5, P< 0.05).
Conclusions Nonspecific systemic stimulation of the innate immune system concurrently with arterial vascular injury facilitates neointimal formation, and conditions associated with increased inflammation may increase restenosis.
Key Words: balloon stents inflammation leukocytes restenosis
| Introduction |
|---|
|
|
|---|
Inflammatory cells are activated promptly after vascular injury1 and recruited to the site of injury.25 These cells are capable of releasing mediators that facilitate smooth muscle cell (SMC) migration and proliferation.68 In human studies, the severity of postangioplasty luminal loss has been found to correlate with activation of circulating leukocytes,9 and restenosis in patients undergoing directional atherectomy has been determined to be correlated with the percentage of macrophages in retrieved tissue at the time of angioplasty.10 Recently, polymorphism of the gene for interleukin (IL)-1 receptor antagonist, a protein that regulates inflammatory response, was found to be associated with reduced restenosis.11 Several antiinflammatory strategies have successfully limited neointimal hyperplasia after injury in animal models. Deactivation of circulating monocytes by IL-1012 and blocking leukocyte adhesion by use of an antibody (Ab) directed against the ß2-integrin Mac-1 (CD11b/CD18)13 reduce neointimal formation after balloon injury and/or stent deployment in rabbits. Furthermore, vascular injury in Mac-1deficient mice is associated with reduced leukocyte accumulation and reduced neointimal formation.14
The fundamental questions that arise are whether the stimulation of inflammation in vascular repair is specific or general and whether inflammation is localized to and controlled only at the site of injury alone or is responsive to systemic modulation. If injury is mediated by a specific inflammatory signal, then this specific pathway needs to be fully delineated and then targeted. Similarly, if the inflammatory process is local, then local therapy alone may suffice, whereas systemic inflammation might require systemic therapy. Finally, a systemic nonspecific response would be sensitive to preexisting inflammation and other inflammatory events, whereas specific localized effects would not. The present study was designed to examine these issues. Rabbits subjected to iliac artery balloon injury, with or without stent deployment, were assigned to bacterial lipopolysaccharide (LPS) injection immediately before and 1 day after the procedure. We report that activation of the innate immune system by LPS is associated with an increased neointimal formation and luminal loss after vascular injury. Furthermore, this augmentation of neointimal growth is blocked by administration of a monoclonal Ab (mAb) directed against CD14.
| Methods |
|---|
|
|
|---|
Hemodynamics
The left common carotid artery was cannulated with a polyethylene catheter for blood pressure measurement (Gould Inc). Systemic blood pressure, heart rate, and respiratory rate were recorded under baseline conditions every minute for 30 minutes after LPS injection and at 30-minute intervals up to 8 hours.
Arterial Harvest and Analysis
Rabbits were euthanized by pentobarbital overdose. Iliac arteries were perfusion fixed with 10% neutral buffered formalin at physiological pressure. Balloon-injured arteries were embedded in paraffin, and 4 to 6 sections 5 µm thick were cut from 3 equally spaced locations. Stented arteries were oriented longitudinally and embedded with a methacrylate formulation. Multiple 5-µm-thick sections were cut with a tungsten carbide knife (Delaware Diamond Knives) on an automated microtome (Leica, Inc) from the proximal and distal ends and the midpoint of each stented segment. Measurements on Verhoeffs tissue elastinstained sections were performed by use of Scion Image software (Scion Corp) running on a computer-assisted digital camera system (Sony Co) interfaced to a Nikon microscope. All sites were analyzed, and the results were averaged.
Immunohistochemistry
Species-specific antibodies were used to immunocytochemically identify macrophages (RAM 11, Dako Co). Rabbit spleen was used as a positive control; a nonspecific isotype Ab was used as a negative control. Standard immunocytochemical protocols were used in conjunction with heat-induced epitope retrieval. Deparaffinized and rehydrated sections were heated in a microwave for 20 minutes in 1x Target Retrieval Solution (Dako), quenched with peroxidase, then incubated with the primary Ab (RAM-11 or nonspecific Ig) for 1 hour, followed by detection with the EnVision+ system (Dako). Sections were counterstained with Mayers hematoxylin, then dehydrated and mounted. The RAM-11positive cells, identified by brown staining, were divided by the total number of intimal and medial cells (3 sections for each slide).
Determination of Monocyte Activation
CD14 Expression on Monocytes
CD14 is a protein essential for LPS-induced cellular activation. CD14 expression is increased in the activated monocyte. The activation status of monocytes was examined in triplicate by fluorescence-activated cell sorting (FACS) with fluorescent anti-CD14 antibodies. Anticoagulated blood was incubated for 30 minutes (200 µL, 4°C, in the dark) with mouse anti-human R-phycoerythrinconjugated anti-CD14 (4 µL, Dako). FACS lysing solution (Becton Dickinson) was added for 15 minutes, and the residual cells were washed 3 times in FACS medium (PBS, 1% BSA, 0.02% sodium azide) (x1500 rpm, 5 minutes, 4°C). Cells were then suspended in 1 mL of FACS medium, and flow cytometry was performed within 1 hour (Becton Dickinson flow cytometer). Monocytes were identified according to their forward- and side-scattering properties as well as fluorescence.
Serum IL-1ß Determination
IL-1ß is a major product of monocytes, secreted in response to LPS. Serum was separated and stored at -70°C until further analysis. After it was thawed, IL-1ß levels were measured in triplicate with a commercial ELISA kit (Biosource International).
Statistical Analysis
All data are presented as mean±SEM. Comparisons between treatment groups used an unpaired, 2-tailed t test. Values of P<0.05 were considered significant.
| Results |
|---|
|
|
|---|
|
Effect of LPS on Stent-Induced Intimal Hyperplasia
Not unexpectedly, intimal hyperplasia in control arteries implanted with NIR stents was relatively modest, with an intimal area of 0.57±0.07 mm2 and stenosis of 9±1%. LPS treatment increased neointimal area significantly, by 35%, to 0.77±0.1 mm2 and stenosis by 44%, to 13±1.7% (Figure 2; n=5, P<0.05 for both intimal area and stenosis). Medial area was unchanged and luminal area was reduced insignificantly by LPS (5.81±0.6 and 5.2±0.33 mm2, control and LPS-treated, respectively).
|
Immunohistochemical Staining for Leukocytes
Macrophage infiltration into the injured arterial wall was recorded at 7 days after injury. LPS administration resulted in an increase in RAM11-positive cells in the vessel wall from 1.7± 1.2% of total cells to 4.2±1.8% (Figure 3; n=4, P<0.05).
|
CD14 Expression on Blood Monocytes
CD14 expression on circulating monocytes was increased significantly in LPS-treated animals compared with injured controls. At 6 hours after vascular injury, there was a 120±25% increase in CD14 expression after LPS treatment, whereas no change was recorded in controls (n=4; Figure 4). Expression at 24 hours was increased by 64% and 30% in LPS-treated animals and controls, respectively. Anti-CD14 Ab administration was associated with complete disappearance of CD14-positive monocytes at 24 hours after injection (data not shown).
|
Serum IL-1ß
IL-1ß levels in serum were increased at 6 hours after injury in both control and LPS-treated rabbits. At 24 hours after injury, IL-1ß levels were increased by 79% over baseline levels in LPS-treated animals (Figure 5A) and reduced by 25% in controls (from 530±163 to 950±53 pg/mL and 474±273 to 352±162 pg/mL, LPS and control, respectively, mean±SD; n=3 in each group; P=0.016). To examine the predictive value of early nonspecific stimulation of the innate immune system on late intimal hyperplasia, the serum IL-1ß change over baseline at 24 hours after injury was correlated with the N/M ratio at 30 days. A strong positive correlation was demonstrated (r2=0.88), with the highest increase in IL-1ß associated with the maximal N/M ratio (Figure 5B).
|
| Discussion |
|---|
|
|
|---|
Monocytes, macrophages, and neutrophils are immediately activated in response to infection and injury,17 including vascular mechanical injury.1 Neutrophils infiltrate an injured vessel wall rapidly, followed by monocytes.35 Adaptive T lymphocytemediated immune responses are probably not involved in neointimal proliferation after balloon dilatation.18 Thrombin-activated platelets and increased monocyte chemoattractant protein-1 expression by injured endothelial cells are among the stimuli that activate monocytes after vascular injury. Macrophages express numerous growth factors, cytokines, and enzymes that facilitate SMC migration and proliferation.8 Systemic modulation of macrophage function inhibits neointimal formation by various modalities, including IL-10 deactivation of monocytes12 and mAb blockade of Mac-1, a ß2-integrin expressed on leukocytes.13
LPS administration stimulates blood monocytes, which increases production and secretion of growth factors. When administered with vascular balloon injury, LPS activated blood monocytes, increased systemic production of IL-1ß, and increased local vascular infiltration of macrophages, all associated with increased intimal hyperplasia. Even in an injury model in which the hyperplastic response is minimal, ie, after implantation of clinically available stents, LPS increased both inflammation and injury. Both systemic secretion of inflammatory mediators and/or increased arrival of highly activated monocytes to the site of injury may explain increased intimal growth. The early increase in serum IL-1ß and its correlation with further intimal growth may indicate that systemic secretion is associated with the late growth effect, whereas the increased macrophage infiltration supports a local effect. The 2 mechanisms, however, may be interrelated. The proinflammatory cytokine IL-1ß increases adhesion of leukocytes to SMCs through increased expression of intercellular adhesion molecule-1 and CD 44 and increases IL-6 production by SMCs. Thus, IL-1ß may indirectly affect SMC activation and proliferation and matrix formation, positively correlating with postinjury neointimal formation.
LPS affects cells involved in healing of vascular injury other than CD14-positive leukocytes. It can cause endothelial vacuolization and desquamation19,20 at much higher doses than those used in this study and increases intercellular adhesion molecule-1 expression on these cells.21 LPS induces the expression of procoagulant tissue factor in epithelial cells22 and activates vascular SMCs,23 probably through soluble CD14 receptors.23 In the present study, blockade of these receptors by mAbs abolished the enhanced formation of neointima after LPS. Thus, additional mechanisms other than the activation of CD14-positive monocytes may underlie the effect observed in this study. Interestingly, total blockade of CD14 in animals not treated with LPS had no effect on neointimal formation (Figure 1E). Thus, the inflammatory response that can affect vascular healing is secondary to several different stimuli, of which CD14-activation is but one.
Although "nonspecific" antiinflammatory drugs effectively reduce neointimal formation and restenosis after experimental vascular injury in a wide variety of models, their effects have not been reproduced in randomized clinical trials. The discrepancy and lack of clinical efficacy may result from inadequate dosing24; from the increased inflammation associated with the surgery performed in animals before arteriotomy, unlike the "minimal" percutaneous procedure performed in humans; or from the large burden of inflammatory cells already present in human atherosclerotic lesions and the inability of the antiinflammatory regimen to block the acute-phase innate response. In 2 clinical trials in which systemic glucocorticoids failed to affect restenosis, methylprednisolone was injected <24 hours before PCI with25 or without26 continuous steroid therapy. This mode of administration may initially stimulate macrophages,27,28 and it may be that the rapid macrophage trafficking to the injured vessel5 requires a more immediate and macrophage-specific systemic antiinflammatory protocol.
The association of a nonspecific inflammatory response and increased neointimal formation may have relevance for certain clinical situations associated with higher rates of adverse outcome, such as end-stage renal failure and dialysis,29 both of which involve constant activation and phenotypic modulation of monocytes30 that may affect their activity when recruited to the site of injury.
Systemic inflammation caused by infection, unrelated to the vascular injury, can modify the healing process. Cytomegalovirus infection increased neointimal formation after balloon injury, 31 probably via systemic inflammatory changes.32 On the basis of the present study, we may assume that the inflammatory response that affects vascular healing is not pathogen specific.
Clinical or subclinical bacteremia may accompany up to 8% of PCIs.33,34 Although completely asymptomatic and subclinical, such bacteremia may stimulate the innate immune system, which in turn affects the long-term results of PCI. Thus, special caution regarding the prevention and detection of infection is warranted.
In conclusion, nonspecific systemic stimulation of the innate immune system concurrently with arterial injury is associated with increased neointimal formation, creating a cycle of injury and inflammation, which contribute to and stimulate each other. These findings add to our understanding of how the outcome of PCIs may differ, the lack of correlation between experimental and clinical studies, and how systemic inflammation should be considered and minimized whenever possible in the setting of intracoronary interventions.
Received December 27, 2001; revision received March 28, 2002; accepted March 28, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. Mollace, S. Ragusa, I. Sacco, C. Muscoli, F. Sculco, V. Visalli, E. Palma, S. Muscoli, L. Mondello, P. Dugo, et al. The Protective Effect of Bergamot Oil Extract on Lecitine-like OxyLDL Receptor-1 Expression in Balloon Injury-related Neointima Formation Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 120 - 129. [Abstract] [PDF] |
||||
![]() |
C. Brasselet, E. Durand, F. Addad, F. Vitry, G. Chatellier, C. Demerens, M. Lemitre, R. Garnotel, D. Urbain, P. Bruneval, et al. Effect of local heating on restenosis and in-stent neointimal hyperplasia in the atherosclerotic rabbit model: a dose-ranging study Eur. Heart J., February 1, 2008; 29(3): 402 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Liu, M. Han, and J.-K. Wen Acetylbritannilactone Inhibits Neointimal Hyperplasia after Balloon Injury of Rat Artery by Suppressing Nuclear Factor-{kappa}B Activation J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 292 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. Lin, Y.-H. Chen, Y.-W. Lin, J.-S. Tsai, J.-W. Chen, H.-J. Wang, Y.-L. Chen, C.-Y. Li, and S.-J. Lin The Role of Human Antigen R, an RNA-binding Protein, in Mediating the Stabilization of Toll-Like Receptor 4 mRNA Induced by Endotoxin: A Novel Mechanism Involved in Vascular Inflammation Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2622 - 2629. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. Lin, Y.-H. Chen, J.-S. Tasi, J.-W. Chen, T.-L. Yang, H.-J. Wang, C.-Y. Li, Y.-L. Chen, and S.-J. Lin Endotoxin Induces Toll-Like Receptor 4 Expression in Vascular Smooth Muscle Cells via NADPH Oxidase Activation and Mitogen-Activated Protein Kinase Signaling Pathways Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2630 - 2637. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Gomes and E. Buffolo Coronary stenting and inflammation: implications for further surgical and medical treatment. Ann. Thorac. Surg., May 1, 2006; 81(5): 1918 - 1925. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tan, Z. Ma, L. Han, R. Du, L. Zhao, X. Wei, D. Hou, B. H. Johnstone, M. R. Farlow, and Y. Du Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2265 - H2271. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Gupta, L. Dai, G. Datta, D. W. Garber, H. Grenett, Y. Li, V. Mishra, M. N. Palgunachari, S. Handattu, S. H. Gianturco, et al. Inhibition of Lipopolysaccharide-Induced Inflammatory Responses by an Apolipoprotein AI Mimetic Peptide Circ. Res., August 5, 2005; 97(3): 236 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. LaDisa Jr., Lars. E. Olson, R. C. Molthen, D. A. Hettrick, P. F. Pratt, M. D. Hardel, J. R. Kersten, D. C. Warltier, and P. S. Pagel Alterations in wall shear stress predict sites of neointimal hyperplasia after stent implantation in rabbit iliac arteries Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2465 - H2475. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. LaDisa Jr., L. E. Olson, I. Guler, D. A. Hettrick, J. R. Kersten, D. C. Warltier, and P. S. Pagel Circumferential vascular deformation after stent implantation alters wall shear stress evaluated with time-dependent 3D computational fluid dynamics models J Appl Physiol, March 1, 2005; 98(3): 947 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Z.H. Rittersma, J. A. Kremer Hovinga, K. T. Koch, S. M. Boekholdt, B. E. van Aken, A. Scheepmaker, M. Bax, C. E. Schotborgh, J. J. Piek, J. G.P. Tijssen, et al. Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms Clin. Chem., March 1, 2005; 51(3): 516 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Muscoli, I. Sacco, W. Alecce, E. Palma, R. Nistico, N. Costa, F. Clementi, D. Rotiroti, F. Romeo, D. Salvemini, et al. The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 44 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Edfeldt, A. M Bennet, P. Eriksson, J. Frostegard, B. Wiman, A. Hamsten, G. K Hansson, U. d. Faire, and Z.-q. Yan Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction Eur. Heart J., August 2, 2004; 25(16): 1447 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Park, H.-S. Kim, H.-M. Yang, K.-W. Park, S.-W. Youn, S.-I. Jeon, D.-H. Kim, B.-K. Koo, I.-H. Chae, D.-J. Choi, et al. Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 885 - 891. [Abstract] [Full Text] |
||||
![]() |
M. Schillinger, W. Mlekusch, R. M. Wolfram, A. C. Budinsky, M. Exner, H. Rumpold, O. Wagner, B. Pokrajac, R. Potter, and E. Minar Endovascular Brachytherapy: Effect on Acute Inflammatory Response after Percutaneous Femoropopliteal Arterial Interventions Radiology, February 1, 2004; 230(2): 556 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Colombo and G. Sangiorgi The monocyte: the key in the lock to reduce stent hyperplasia? J. Am. Coll. Cardiol., January 7, 2004; 43(1): 24 - 26. [Full Text] [PDF] |
||||
![]() |
H. D. Danenberg, G. Golomb, A. Groothuis, J. Gao, H. Epstein, R. V. Swaminathan, P. Seifert, and E. R. Edelman Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits Circulation, December 2, 2003; 108(22): 2798 - 2804. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mandinov, A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, V. Kolev, R. Soldi, C. Bagala, E. D. de Muinck, V. Lindner, et al. Copper chelation represses the vascular response to injury PNAS, May 27, 2003; 100(11): 6700 - 6705. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Shah Inflammation, Neointimal Hyperplasia, and Restenosis: As the Leukocytes Roll, the Arteries Thicken Circulation, May 6, 2003; 107(17): 2175 - 2177. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||